Eisai’s Alzheimer’s disease treatment drug Boutichi Ryoyaku has been approved in the United States.
日本の製薬大手「エーザイ」などが開発したアルツハイマー病の新たな治療薬がアメリカで承認されました
A new therapeutic agent for Alzheimer’s disease, developed by Japanese pharmaceutical giant Eisai and others, has been approved in the United States.
An application for approval in Japan is also being considered.
The US FDA = Food and Drug Administration is scheduled to be released on the 6th, and Eisai and the US pharmaceutical giant Biogen have jointly developed a therapeutic drug for Alzheimer’s disease. Recently, for lecanemab, a special and special approval called accelerated approval was given.
”Lecanemab” was confirmed to be effective in delaying the worsening of symptoms by 27% in clinical trials at the final stage of the study. This has led to the approval of the company.
Approval applications are being considered in Japan and Europe
Home
Video
JLPT Test
Dictionary
Lesson
Topic
